

ASX ANNOUNCEMENT

Benitec's securities trading on a consolidated basis

Sydney, 19 July 2013: Benitec Biopharma Ltd (ASX: BLT) announced today that following the General Meeting on 17 July 2013 and in accordance with the timetable set out in the Notice of Meeting, trading will commence today in consolidated securities (on the basis of a 25:1 consolidation of issued securities) on a deferred settlement basis (Code: BLTDA for shares).

For more information please contact: Greg West | Company Secretary
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.